Kovitz Investment Group Partners LLC Has $1.76 Million Stake in Boston Scientific Co. (NYSE:BSX)

Kovitz Investment Group Partners LLC grew its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 0.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 19,691 shares of the medical equipment provider’s stock after acquiring an additional 178 shares during the quarter. Kovitz Investment Group Partners LLC’s holdings in Boston Scientific were worth $1,759,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of BSX. TFC Financial Management Inc. increased its stake in shares of Boston Scientific by 308.8% in the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 210 shares during the period. Global Wealth Strategies & Associates increased its stake in shares of Boston Scientific by 423.7% in the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 250 shares during the period. West Oak Capital LLC acquired a new position in shares of Boston Scientific in the fourth quarter valued at approximately $29,000. Valley National Advisers Inc. increased its stake in shares of Boston Scientific by 262.4% in the fourth quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 286 shares during the period. Finally, Fairway Wealth LLC acquired a new position in shares of Boston Scientific in the fourth quarter valued at approximately $36,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Up 0.3 %

Boston Scientific stock opened at $102.17 on Tuesday. Boston Scientific Co. has a fifty-two week low of $70.97 and a fifty-two week high of $107.17. The stock has a market cap of $151.12 billion, a PE ratio of 81.74, a price-to-earnings-growth ratio of 2.79 and a beta of 0.73. The firm’s 50-day simple moving average is $98.62 and its 200 day simple moving average is $95.03. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The business had revenue of $4.66 billion for the quarter, compared to analysts’ expectations of $4.57 billion. During the same period in the previous year, the company earned $0.56 earnings per share. The firm’s revenue for the quarter was up 20.9% compared to the same quarter last year. Research analysts predict that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on BSX. Royal Bank of Canada upped their price objective on Boston Scientific from $116.00 to $120.00 and gave the company an “outperform” rating in a research note on Thursday, April 24th. Morgan Stanley boosted their target price on shares of Boston Scientific from $100.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. BTIG Research restated a “buy” rating and issued a $124.00 target price on shares of Boston Scientific in a report on Wednesday, April 23rd. Barclays boosted their target price on shares of Boston Scientific from $118.00 to $125.00 and gave the company an “overweight” rating in a report on Friday. Finally, Citigroup boosted their target price on shares of Boston Scientific from $107.00 to $122.00 and gave the company a “buy” rating in a report on Thursday, February 6th. One equities research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Boston Scientific presently has a consensus rating of “Buy” and a consensus target price of $114.52.

Insider Buying and Selling

In related news, SVP Vance R. Brown sold 4,826 shares of the business’s stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $95.09, for a total transaction of $458,904.34. Following the transaction, the senior vice president now directly owns 36,193 shares in the company, valued at approximately $3,441,592.37. The trade was a 11.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Daniel J. Brennan sold 15,087 shares of the business’s stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $105.07, for a total transaction of $1,585,191.09. Following the completion of the transaction, the chief financial officer now owns 241,451 shares in the company, valued at approximately $25,369,256.57. The trade was a 5.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 138,009 shares of company stock worth $14,407,381. 0.50% of the stock is owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.